Breast cancer | Prostate cancer | Other solid tumours | |
---|---|---|---|
SRE rate (per year) | |||
Zoledronic acid | 0.631 | 0.947 | 0.936 |
Denosumab (derived) | 0.486 | 0.777 | 0.796 |
Denosumab treatment effect | |||
Rate ratio first and subsequent SRE | 0.77 | 0.82 | 0.85 |
SRE type distribution* (%) | |||
Pathologic fracture | 58.2 | 26.8 | 31.4 |
Radiation to bone | 35.4 | 66.1 | 57.5 |
Surgery to bone | 4.7 | 1.5 | 6.2 |
Spinal cord compression | 1.7 | 5.6 | 5.0 |
*Pooled across both treatment groups.
SRE, skeletal-related event.